Literature DB >> 7987173

Therapeutic use of bisphosphonates in oncology.

R E Coleman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7987173      PMCID： PMC2541696          DOI： 10.1136/bmj.309.6963.1233b

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

Review 1.  Osteoclast inhibition for the treatment of bone metastases.

Authors:  R E Coleman; O P Purohit
Journal:  Cancer Treat Rev       Date:  1993-01       Impact factor: 12.111

Review 2.  The therapeutic use of bisphosphonates.

Authors:  J E Compston
Journal:  BMJ       Date:  1994-09-17

3.  Palliative pamidronate treatment in patients with bone metastases from breast cancer.

Authors:  A T van Holten-Verzantvoort; H M Kroon; O L Bijvoet; F J Cleton; L V Beex; G Blijham; J Hermans; J P Neijt; S E Papapoulos; H P Sleeboom
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

4.  Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas.

Authors:  F B Hagemeister; R Khetan; P Allen; P McLaughlin; M A Rodriguez; F Swan; J E Romaguera; F Cabanillas
Journal:  Ann Oncol       Date:  1994       Impact factor: 32.976

5.  Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.

Authors:  R Lahtinen; M Laakso; I Palva; P Virkkunen; I Elomaa
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321
  5 in total
  1 in total

1.  The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.

Authors:  H A Harvey; A Lipton
Journal:  Support Care Cancer       Date:  1996-05       Impact factor: 3.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.